You are here
EndoBarrier receives German reimbursement for T2DM
InEk, the German Institute for the Hospital Remuneration System, has awarded GI Dynamics’ EndoBarrier NUB Status 1 for 2017. The NUB process allows for introduction of new and innovative medical devices prior to reaching reimbursement eligibility, and provides for a supplemental payment for new technologies in the German reimbursement system. NUB Status 1 is the highest of four levels, as it allows for full reimbursement for the 143 participating hospitals in 2017. Under NUB Status 1, payers at these hospitals are obligated to cover the gaps in treatment costs for the EndoBarrier procedure.
“The NUB 1 designation is an important step towards full reimbursement for EndoBarrier in Germany, where there is a significant need for additional therapeutic options for patients with type 2 diabetes and obesity,” said Scott Schorer, president and chief executive officer of GI Dynamics. “We look forward to continuing our work with clinical teams in Germany to restore healthy blood sugar levels and achieve weight loss in this patient population.”
EndoBarrier is a minimally invasive, non-pharmaceutical therapy for patients living with uncontrolled type 2 diabetes and obesity. The EndoBarrier liner is a flexible sleeve placed inside the intestine to create a physical barrier between the intestinal wall and ingested food. Clinical data suggest that EndoBarrier works by affecting key hormones involved in insulin sensitivity, glucose metabolism, satiety and food intake. EndoBarrier is currently approved for sale in several countries outside of the United States.